Research Paper Volume 13, Issue 2 pp 1729—1741

Anserine, HClO-scavenger, protected against cognitive decline in individuals with mild cognitive impairment

Nobutaka Masuoka1, *, , Chenxu Lei1, , Haowei Li1, , Noriko Inamura2,3, , Shigenobu Shiotani4, , Nobuya Yanai4, , Kenichiro Sato4, , Keisuke Sakurai1, , Tatsuhiro Hisatsune1, ,

  • 1 Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan
  • 2 Community Hearth Promotion Laboratory, Mitsui Fudosan, Co., Ltd., Kashiwa, Japan
  • 3 Urban Design Center Kashiwanoha (UDCK), Kashiwa, Japan
  • 4 Research Division, Tokai Bussan Co., Ltd., Tokyo, Japan
* Present address: Hojo Clinic, Shinagawa, Tokyo, Japan

Received: May 6, 2020       Accepted: December 18, 2020       Published: January 20, 2021
How to Cite

Copyright: © 2021 Masuoka et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Neuroinflammation has been recognized as a promising target when considering strategies for treating AD. In particular, it has been shown that neutrophils and MPO-mediated neuroinflammatory responses with the production of HClO play a role in the progression of AD. In this study, we aimed to evaluate the effects of anserine, a scavenger of HClO, on the protection of cognitive declines in persons with MCI. Fifty-eight elderly volunteers were screened, and 36 MCI individuals were assigned either to an active arm, who received 500 mg anserine per day, or a placebo arm, for 12-weeks. To assess cognitive function, we performed MMSE at baseline and after the ingestion. The data of the MMSE for 30 subjects who completed the follow-up tests were analyzed. A significant difference was detected in the change score of MMSE between the active arm (1.9 ± 2.0; n = 15) and the placebo arm (0 ± 2.8; n = 15) (p = 0.036). After the correction with the daily intake of anserine, the significance was elevated (p = 0.0176). Our results suggest that anserine protects elderly persons with MCI from cognitive declines by suppressing MPO-mediated neuroinflammatory responses.


AD: Alzheimer’s disease; MPO: Myeloperoxidase; HClO: Hypochlorous acid; MMSE: Mini-Mental State Examination; MCI: Mild cognitive impairment; ACS: Anserine/carnosine supplementation.